Aptar’s Activ-Film™ Technology Selected to Protect New SARS Rapid Antigen Test for COVID-19 Diagnosis
Crystal Lake, Illinois, February 16, 2021 - AptarGroup, Inc.
(NYSE: ATR), a global leader in drug delivery, consumer product
dispensing and active packaging solutions, announced that its
Activ-Film™ technology was selected to protect a new SARS Rapid Antigen
test for COVID-19 that recently received Emergency Use Authorization
(EUA) from the U.S. Food and Drug Administration (FDA).
More info >> |